BACKGROUND: Intoxication by nerve agents could be prevented by using small acetylcholinesterase inhibitors (eg, pyridostigmine) for potentially exposed personnel. However, the serious side effects of currently used drugs led to research of novel potent molecules for prophylaxis of organophosphorus intoxication. METHODS: The molecular design, molecular docking, chemical synthesis, in vitro methods (enzyme inhibition, cytotoxicity, and nicotinic receptors modulation), and in vivo methods (acute toxicity and prophylactic effect) were used to study bispyridinium, bisquinolinium, bisisoquinolinium, and pyridinium-quinolinium/isoquinolinium molecules presented in this study. RESULTS: The studied molecules showed non-competitive inhibitory ability towards human acetylcholinesterase in vitro that was further confirmed by molecular modelling studies. Several compounds were selected for further studies. First, their cytotoxicity, nicotinic receptors modulation, and acute toxicity (lethal dose for 50% of laboratory animals [LD50]; mice and rats) were tested to evaluate their safety with promising results. Furthermore, their blood levels were measured to select the appropriate time for prophylactic administration. Finally, the protective ratio of selected compounds against soman-induced toxicity was determined when selected compounds were found similarly potent or only slightly better to standard pyridostigmine. CONCLUSION: The presented small bisquaternary molecules did not show overall benefit in prophylaxis of soman-induced in vivo toxicity.

Biomedical Research Center University Hospital Hradec Kralove

Department of Chemistry Faculty of Science University of Hradec Kralove

Department of Neurology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Toxicology and Military Pharmacy Faculty of Military Health Sciences University of Defence

Zobrazit více v PubMed

Marrs TC. Organophosphate anticholinesterase poisoning. Toxic Subst Mech. 1996;15:357–388.

Bajgar J, Fusek J, Kuca K, Bartosova L, Jun D. Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev Med Chem. 2007;7(5):461–466. PubMed

Patocka J, Jun D, Bajgar J, Kuca K. Prophylaxis against nerve agent intoxications. Def Sci J. 2006;56:775–784.

Sepsova V, Karasova JZ, Zemek F, Bennion B, Kuca K. Oximes as inhibitors of acetylcholinesterase – a structure-activity relationship (SAR) study. Mil Med Sci Lett. 2011;80:178–186. PubMed PMC

Masson P, Josse D, Lockridge O, Viguie N, Taupin C, Buhler C. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. J Physiol Paris. 1998;92(5–6):357–362. PubMed

Masson P, Nachon F. Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning. J Neurochem. 2017;142(Suppl 2):26–40. PubMed

Harris LW, Heyl WC, Stitcher DL, Broomfield CA. Effects of 1, 1′-oxydimethylene bis-(4-tert-butylpyridinium chloride) (SAD-128) and decamethonium on reactivation of soman-inhibited and sarin-inhibited cholinesterase by oximes. Biochem Pharmacol. 1978;27(5):757–761. PubMed

Alkondon M, Albuquerque EX. The nonoxime bispyridinium compound SAD-128 alters the kinetic properties of the nicotinic acetylcholine receptor ion channel: a possible mechanism for antidotal effects. J Pharmacol Exp Ther. 1989;250(3):842–852. PubMed

Kloog Y, Sokolovsky M. Bisquaternary pyridinium oximes as allosteric inhibitors of rat brain muscarinic receptors. Mol Pharmacol. 1985;27:418–428. PubMed

Lundy PM, Tremblay KP. Ganglion blocking properties of some bispyridinium soman antagonists. Eur J Pharmacol. 1979;60(1):47–53. PubMed

Musilek K, Komloova M, Zavadova V, et al. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage – initial study for Myasthenia gravis implications. Bioorg Med Chem Lett. 2010;20:1763–1766. PubMed

Musilek K, Komloova M, Holas O, et al. Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage – implications for early Myasthenia gravis treatment. Eur J Med Chem. 2011;46:811–818. PubMed

Komloova M, Musilek K, Horova A, et al. Preparation, in vitro screening and molecular modelling of symmetrical bisquinolinium cholinesterase inhibitors – implications for early Myasthenia gravis treatment. Bioorg Med Chem Lett. 2011;21:2505–2509. PubMed

Komloova M, Horova A, Hrabinova M, et al. Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors. Bioorg Med Chem Lett. 2013;23(24):6663–6666. PubMed

Musilek K, Pavlikova R, Komloova M, et al. Preparation, in vitro screening and molecular docking of symmetrical bisquaternary cholinesterase inhibitors bearing but-(2E)-en-1,4-diyl connecting linkage. J Enzym Inhib Med Chem. 2011;26:245–253. PubMed

Musilek K, Roder J, Komloova M, et al. Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors – analogues of SAD-128. Bioorg Med Chem Lett. 2011;21(1):150–154. PubMed

Musilek K, Kucera J, Jun D, Dohnal V, Opletalova V, Kuca K. Mono-quaternary pyridinium salts with modified side chain–synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase. Bioorg Med Chem. 2008;16(17):8218–8223. PubMed

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 1983;65(1–2):55–63. PubMed

Sepsova V, Krusek J, Zdarova-Karasova J, et al. The interaction of quaternary reversible acetylcholinesterase inhibitors with the nicotinic receptor. Physiol Res. 2014;63(6):771–777. PubMed

Kassa J, Korábečný J, Nepovimová E. The evaluation of benefit of newly prepared reversible inhibitors of acetylcholinesterase and commonly used pyridostigmine as pharmacological pretreatment of soman-poisoned mice. Acta Medica (Hradec Kralove) 2017;60(1):37–43. PubMed

Kassa J, Kuca K, Bartosova L, Kunesova G. The development of new structural analogues of oximes for the antidotal treatment of poisoning by nerve agents and the comparison of their reactivating and therapeutic efficacy with currently available oximes. Curr Org Chem. 2007;11(3):267–283.

Musilek K, Jun D, Cabal J, Kassa J, Gunn-Moore F, Kuca K. Design of a potent reactivator of tabun-inhibited acetylcholinesterase – synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)-but-2-ene dibromide (K203) J Med Chem. 2007;50(22):5514–5518. PubMed

Karasova JZ, Hroch M, Musilek K, Kuca K. Small quaternary inhibitors K298 and K524: cholinesterases inhibition, absorption, brain distribution, and toxicity. Neurotox Res. 2016;29(2):267–274. PubMed

Meyer HG, Lukey BJ, Gepp RT, Corpuz RP, Lieske CN. A radioimmunoassay for pyridostigmine. J Pharmacol Exp Ther. 1988;247:432–438. PubMed

Karasova JZ, Hnidkova D, Pohanka M, Musilek K, Chilcott RP, Kuca K. Pharmacokinetics of acetylcholinesterase reactivator K203 and consequent evaluation of low molecular weight antioxidants/markers of oxidative stress. J Appl Biomed. 2012;10:71–78.

Karasova JZ, Chladek J, Hroch M, Fusek J, Hnidkova D, Kuca K. Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma. J Appl Toxicol. 2013;33(1):18–23. PubMed

Karasova JZ, Novotny L, Antos K, Zivna H, Kuca K. Time-depend changes in concentration of two clinically used acetylcholinesterase reactivators (HI-6 and obidoxime) in rat plasma determined by HPLC techniques after in vivo administration. Anal Sci. 2010;26:63–67. PubMed

Kassa J, Musilek K, Koomlova M, Bajgar J. A comparison of the efficacy of newly developed reversible inhibitors of acetylcholinesterase with commonly used pyridostigmine as pharmacological pre-treatment of soman-poisoned mice. Bas Clin Pharm Tox. 2012;110(4):322–326. PubMed

Tallarida R, Murray R. Manual of Pharmacological Calculation with Computer Programs. New York: Springer-Verlag; 1987.

Lorke DE, Nurulain SM, Hasan MY, Kuca K, Petroianu GA. Prophylactic administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using terbufos sulfone. J Appl Toxicol. 2014;34(10):1096–1103. PubMed

Lorke DE, Hasan MY, Nurulain SM, Shafiullah M, Kuca K, Petroianu GA. Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: assessment using methyl-paraoxon. CNS Neurol Disord Drug Targets. 2012;11(8):1052–1060. PubMed

Petroianu GA, Nurulain SM, Shafiullah M, Hasan MY, Kuca K, Lorke DE. Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon. J Appl Toxicol. 2013;33(9):894–900. PubMed